乳腺癌激素受体与肿瘤标记物联合检测对乳腺癌预后的影响  

Relationshiop between the joint inspection of hormone receptor and tumor markers and prognosis of patients with breast cancer

作　　者：唐芳勇[1] 李凤玲[1] 王维生[1] 郭少敏[1] 刘翠云[1] 孙德军[1] 崔勇[1] 吴志先[1] 王建金[1] 

机构地区：[1]山东省寿光市人民医院,262700

出　　处：《中国实用医刊》2010年第21期4-6,共3页Chinese Journal of Practical Medicine

摘　　要：目的 探讨雌激素受体(ER)、孕激素受体(PR)、原癌基因(C-erbB-2)、Ki-67与癌胚抗原(CEA)、糖抗原153(CA-153)联合检测对乳腺癌预后的评估,区分患者的复发危险性,以采取个性化治疗方案,提高患者的长期生存率.方法 120例乳腺癌患者术前检测CEA、CA-153,术中组织标本石蜡切片标本SP法免疫组化检测.结果 120例乳腺癌中ER、PR、C-erbB-2 、Ki-67的阳性表达率分别为62%、51%、38%、73%,CEA、CA-153阳性表达率分别为8%、10%,C-erbB-2、Ki-67与CEA、CA-153的表达与乳腺癌转移与预后呈正相关,ER、PR的表达与乳腺癌转移与预后呈负相关.结论 C-erbB-2、Ki-67与CEA、CA-153的表达是乳腺癌患者预后差的指标,ER、PR的表达提示乳腺癌患者预后好,ER、PR、C-erbB-2、Ki-67与CEA、CA-153联合检测有助于乳腺癌患者的治疗和预后判断.Objective To assess the prognosis of patients with breast cancer through the joint inspection of ER, PR, C-erbB-2, Ki-67 and CEA, CA-153. To differentiate patients relapse risk and adopt personalized management plan,which were to improve the patients with long-term survival. Methods The level of CEA,and CA-153 were measured in 120 breast cancer before the surgery, ER,PR,C-erbB-2 and Ki-67 were measured by SP immunohistochemical staining technique on paraffin-embedded specimens of 120 cases of breast cancer. Results The positive rate in patients with lung cancer of ER, PR, C-erbB-2, Ki-67, CEA and CA-153 were 62%, 51%, 38%, 73%, 8%and 10%, respectively. The expression of C-erbB-2, Ki-67, CEA and CA-153 was positively related to the metastasis and prognosis of breast cancer, with the expression of ER and PR being negatively. Conclusions The joint inspection of ER, PR, C-erbB-2, Ki-67, CEA and CA-153 is valuable to prognosis and treatment of breast cancer.

分 类 号：R737[医药卫生—肿瘤]